Skip to main content

Market Overview

ElectroCore Concludes Enrollment In COVID-19 Study Evaluating Vagus Nerve Stimulation

  • ElectroCore Inc (NASDAQ: ECOR) and the Hospital Clínico Universitario de Valencia in Spain have completed the enrollment in the SAVIOR-1 study. This study was supported in part by electroCore.
  • The randomized, controlled study evaluates the effect of non-invasive electrical vagus nerve stimulation (nVNS) on respiratory symptoms due to COVID-19.
  • In July last year, gammaCore SapphireTM CV (the nVNS) received emergency use authorization from the FDA to treat patients with known or suspected COVID-19 who are experiencing an exacerbation of asthma-related dyspnea and reduced airflow.
  • Price Action: ECOR increased 10.2% at $2.325 on the last check Wednesday.

Related Articles (ECOR)

View Comments and Join the Discussion!

Posted-In: Covid-19Biotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at